Harmony Biosciences Holdings, Inc. (HRMY)

Market Cap	2.20B
Revenue (ttm)	825.94M
Net Income (ttm)	185.68M
Shares Out	57.60M
EPS (ttm)	3.17
PE Ratio	12.07
Forward PE	10.27
Dividend	n/a
Ex-Dividend Date	n/a

Volume	757,269
Open	36.99
Previous Close	37.00
Day's Range	36.86 - 38.80
52-Week Range	25.52 - 40.93
Beta	0.80
Analysts	Strong Buy
Price Target	51.33 (+34.2%)
Earnings Date	Nov 4, 2025

About HRMY

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also develops Pitolisant that is in Phase 3 clinical trial for the treatment of Prader-Willi Syndrome (PWS); in Phase 2 clinical trial to treat Myotonic Dystrophy (DM1); a...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Aug 19, 2020
• Employees: 268
• Stock Exchange: NASDAQ
• Ticker Symbol: HRMY
• Website: https://www.harmonybiosciences.com

Financial Performance

In 2024, HRMY's revenue was $714.73 million, an increase of 22.80% compared to the previous year's $582.02 million. Earnings were $145.49 million, an increase of 12.91%.

Analyst Summary

According to 9 analysts, the average rating for HRMY stock is "Strong Buy." The 12-month stock price target is $51.33, which is an increase of 34.20% from the latest price.

Price Target

$51.33

(34.20% upside)

Analyst Consensus: Strong Buy